Skip to main content

Table 3 Average baseline characteristics in 11 patients with COVID-19

From: Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

  Survivors (n = 6) Non-survivors (n = 5) All (n = 11)
Age (years)* 53.50 ± 10.50 54.20 ± 11.50 53.80 ± 10.40
Sex    
Male 4 (80%) 4 (66.70%) 8 (73%)
Female 1 (20%) 2 (33.30%) 3 (27%)
Comorbid disease 4 2 6 (54.50%)
Fever (> 37.3 °C) 6 (100%) 4 (80%) 10 (91%)
Cough 5 (83.30%) 5 (100%) 10 (91%)
Dyspnea 5 (83.30%) 5 (100%) 10 (91%)
PaO2/FiO2 ratio (IQR) 87.67 (15.00) 69.40 (47.50) 79.39 (35)
Respiratory rate (> 30) 6 (100%) 5 (100%) 11 (100%)
SOFA (min-max) 3–6 3–7 3–7
WBCs 6668 (1451) 14,957 (6581) 10,352 (6160)
Lymphocytes (%) 21.18 (18.00) 5.56 (5.10) 14.08 (8.70)
Lymphocytes < 1000 5 (83%) 4 (80%) 9 (81.8%)
Platelets 199,600 (58439) 178,500 (58563) 190,223 (55831)
PT 15.64 (4.72) 14.50 (0.55) 15.13 (3.41)
PTT 32.60 (11.59) 38.25 (9.95) 35.11 (10.64)
BUN 22.88 (11.26) 35.95 (23.18) 28.69 (17.67)
Cr 1.04 (0.29) 1.76 (1.17) 1.36 (0.83)
LDH 1237 (209) 1122 (500) 1186.33 (345.64)
Median days from first symptom to admission (IQR) 4.5 (10) 11 (4) 10 (10)
Median days from first symptom to first infusion (IQR) 9 (16) 17 (3) 16 (10)
  1. *Except age which is presented as mean ± SD, all data are presented as n (%), or median ± (IQR)
  2. IQR interquartile range, Cr creatinine, SOFA Sequential Organ Failure Assessment